END MONOPOLY ON SALVARSAN

End pharmacists' monopoly on selling certain drugs.

For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for . For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/ All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are...

Salvarsan Poisoning

a spectacular nature as to impress one with its specificity, but in very few cases indeed could such a belief be continued for any length of time. I have noticed that in the majority of cases, either repeated and refractory recurrences have followed, dashing to the ground the fervent hopes of the most optimistic experimenter, or such disastrous consequences have resulted which might well make t...

A Salvarsan Series

Salvarsan – the First Chemotherapeutic Compound

Early History If defined as the use of a specific compound discovered as the result of a systematic search for a cure for a specific disease, then chemotherapy is less than a century old. The first example was the introduction in 1910 by Paul Ehrlich of an organoarsenic compound he named Salvarsan, which provided the first real cure for the extremely unpleasant disease syphilis (caused by the p...

Implications of Monopoly on Innovation

This paper tries to bring together the basic explanation of monopolies and Schumpeterian hypothesis of type and size of firm stimulating innovation by taking into account some literature that relates these two. It is a brief literature synthesis and sets grounds for future empirical research to test the Schumpeterian hypotheses.